Status Awaiting development
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information Topic in appraisal.
Process STA Standard
ID number 6426

Provisional Schedule

Committee meeting: 1 04 March 2025
Expected publication 21 May 2025

Project Team

Project lead Jennifer Upton

Email enquiries

External Assessment Group Warwick Evidence, Warwick Medical School, University of Warwick

Timeline

Key events during the development of the guidance:

Date Update
31 July 2024 Invitation to participate
04 July 2024 Draft scope documents
01 May 2024 Awaiting development. NICE will be undertaking an managed access review of Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. This was originally TA963 The appraisal is expected to start during early-July 2024 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the appraisal during late-July 2024. The deadline for submissions is expected in approximately late-September 2024.
01 May 2024 NICE will be undertaking an managed access review of Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. This was originally TA963 The appraisal is expected to start during early-July 2024 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the appraisal during late-July 2024. The deadline for submissions is expected in approximately late-September 2024.
11 April 2024 In progress

For further information on our processes and methods, please see our CHTE processes and methods manual